Topography of the Photosystem I Core Proteins of the Cyanobacterium Synechocystis sp. PCC 6803*

(Received for publication, May 22, 1997, and in revised form, June 22, 1997)

Jun Sun , Qiang Xu Dagger , Vaishali P. Chitnis , Ping Jin § and Parag R. Chitnis

From the Department of Biochemistry and Biophysics, Iowa State University, Ames, Iowa 50011

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

PsaA and PsaB are homologous integral membrane proteins that form the heterodimeric core of photosystem I. Domain-specific antibodies were generated to examine the topography of PsaA and PsaB. The purified photosystem I complexes from the wild type strain of Synechocystis sp. PCC 6803 were treated with eight proteases to study the accessibility of cleavage sites in PsaA and PsaB. Proteolytic fragments were identified using the information from N-terminal amino acid sequencing, reactivity to antibodies, apparent mass, and specificity of proteases. The extramembrane loops of PsaA and PsaB differed in their accessibility to proteases, which indicated the folded structure of the loops or their shielding by the small subunits of photosystem I. NaI-treated and mutant photosystem I complexes were used to identify the extramembrane loops that were exposed in the absence of specific small subunits. The absence of PsaD exposed additional proteolytic sites in PsaB, whereas the absence of PsaE exposed sites in PsaA. These studies distinguish PsaA and PsaB in the structural model for photosystem I that has been proposed on the basis of x-ray diffraction studies (Krauß, N., Schubert, W.-D., Klukas, O., Fromme, P., Witt, H. T., and Saenger, W. (1996) Nat. Struct. Biol. 3, 965-973). Using osmotically shocked cells for protease treatments, the N terminus of PsaA was determined to be on the n side of the photosynthetic membranes. Based on these data and available published information, we propose a topological model for PsaA and PsaB.


INTRODUCTION

Photosystem I (PS I)1 from cyanobacteria and chloroplasts is a multisubunit membrane-protein complex that catalyzes electron transfer from reduced plastocyanin (or cytochrome c6) to oxidized ferredoxin (or flavodoxin) (1-4). The PsaA and PsaB subunits of PS I form the heterodimeric core of the complex which harbors approximately 100 antenna chlorophyll a molecules, 10-12 beta -carotenes, the primary electron donor P700, and a chain of electron acceptors (A0, A1, and FX). PsaA and PsaB also interact directly with plastocyanin or cytochrome c6 (5-7). In addition to the core proteins, the cyanobacterial PS I complex contains 9 small subunits (1-3). PsaC binds the terminal electron acceptors FA and FB, which are two [4Fe-4S] center (8). PsaD provides an essential ferredoxin-docking site on the reducing side of PS I (9-11) and is required for the stable assembly of PsaC and PsaE into the PS I complex (12, 13). PsaE is involved in ferredoxin docking (10, 14-16) and in cyclic electron flow around PS I (17, 18). PsaF provides a component of the docking site for plastocyanin in the plant PS I (7, 19, 20) but not in the cyanobacterial PS I (6, 21). PsaL is essential for the formation of PS I trimers in cyanobacteria (22). PsaI and PsaJ are required for the correct organization of PsaL and PsaF, respectively (23, 24). The absence of PsaM in cyanobacterial mutants causes deficiency in growth at high light intensity and affects stable assembly of PsaD.2,3 The role of PsaK has not been identified.

During the past few years, major advances in x-ray crystallography (25, 26), electron microscopy (27), molecular genetics (10, 22), and biochemical studies (28, 29) have provided a framework for understanding the overall architecture of PS I. The PS I complex has an elongated shape with a local pseudo-2-fold symmetry. PsaC, PsaD, and PsaE are peripheral subunits, located on the n side (stromal side in chloroplasts and cytoplasmic side in cyanobacteria) of photosynthetic membranes, with PsaC positioned in the center of each monomeric PS I on the axis of symmetry (26, 27). The recent crystal analysis of PS I has indicated the location of [4Fe-4S] clusters FX, FA, and FB, 71 chlorophyll a molecules, 31 transmembrane alpha -helices, and 9 surface and 3 stromal alpha -helices (26). A monomer of PS I consists of a "catalytic domain" and a smaller "connecting domain" that links monomers to form a trimer. The connecting domain contains three transmembrane helices which may belong to PsaL and PsaI (22, 23). The remaining helices belong to the PS I core and other subunits in the catalytic domain. Twenty-two transmembrane and eight peripheral helices in the catalytic domain are arranged in an approximate symmetry (25, 26). Therefore, in agreement with the hydropathy analysis, the PsaA and PsaB cores are proposed to contain 11 transmembrane helices each (30).

Although the x-ray crystallography studies provided information of the PS I core, PsaA and PsaB could not be distinguished at the present resolution (26). Similarly, the interaction between PS I core and small subunits, the surface domains, and residues of the PS I core and positioning of extramembrane loops with respect to the photosynthetic membranes have not been elucidated clearly. Topographical studies provide a valuable tool to understand these unresolved structural features of PS I. In this paper, we describe biochemical studies that used subunit-deficient mutants, limited proteolysis, and domain-specific antibodies. We studied the accessibility of PsaA and PsaB to different proteases, the shielding of PsaA and PsaB by smaller PS I subunits, and the position of the N terminus of PsaA with respect to the membrane plane.


EXPERIMENTAL PROCEDURES

Cyanobacterial Strains and Culture

Strains of Synechocystis sp. PCC 6803 that were used in this study are listed in Table I. Cultures of wild type and mutant strains were grown in BG-11 with or without 5 mM glucose and antibiotics (30 µg/ml chloramphenicol or 40 µg/ml kanamycin) under a light intensity of 21 µmol·m-1·s-1. Cells were harvested at the late exponential growth phase and resuspended in 0.4 M sucrose, 10 mM NaCl, 1 mM PMSF, 2 mM benzamidine, and 10 mM MOPS, pH 7.0, for isolation of thylakoids.

Table I. Strains of Synechocystis sp. PCC 6803 that were used in this study


Strains Description Characteristics of the purified PSI complexes

Wild type Glucose-tolerant strain Eleven subunits resolved upon electrophoresis; capable of light-driven Cyt c6 oxidation and Fda reduction
ADC4 psaD replaced by a chloramphenicol resistance gene PsaD and PsaL missing; no Fd-mediated NADP+ photoreduction (10, 34, 47, 48)
AEK2 psaE replaced by a kanamycin resistance gene Only PsaE missing; reduced Fd-mediated NADP+ photoreduction (10, 49)
AFK6 psaF replaced by a kanamycin resistance gene; psaJ transcriptionally inactivated PsaF and PsaJ missing and level of PsaE decreased; normal rate of P700 reduction by Cyt c6 (6, 10, 21)
AIC9 psaI interrupted by a chloramphenicol resistance gene; psaL transcripts decreased PsaI and PsaL missing; small decrease of Fd-mediated NADP+ photoreduction (23)

a Fd, ferredoxin.

Isolation of the Photosynthetic Membranes and Purification of PS I Complexes

Photosynthetic membranes were isolated after cell breakage with a bead beater (Biospec Products) (28). To isolate PS I, the membranes were solubilized with Triton X-100 and subjected to DEAE-cellulose chromatography and sucrose gradient centrifugation (31). Chlorophyll concentrations in the thylakoid membranes and PS I complexes were determined in 80% (v/v) acetone (32).

Preparation of Osmotically Shocked Cells of Synechocystis sp. PCC 6803

Cells were harvested at the late exponential growth phase by centrifugation (7000 × g, 10 min). The pellet was resuspended in 0.4 M sucrose, 5 mM EDTA, and 10 mM HEPES, pH 7.0, pelleted again, and resuspended in the same buffer with 0.2% (w/v) lysozyme to 1 g of cells per 10 ml. Cell wall was digested by incubation at 27 °C for 12 h under illumination (21 µmol·m-1·s-1) with constant shaking. Cells were harvested by centrifugation (7000 × g, 10 min), resuspended in osmotic shock solution (50 mM potassium phosphate, pH 6.8, 30 mM sodium citrate, 0.2 mM CaCl2, 1 mM PMSF, and 2 mM benzamidine), incubated on ice for 30 min, and harvested by centrifugation (7000 × g, 10 min) again. This osmotic shock treatment was repeated two additional times. The cells were pelleted and resuspended twice with 10 mM NaCl, 10 mM HEPES, pH 7.0, and finally resuspended in 0.4 M sucrose, 10 mM NaCl, 10 mM HEPES, pH 7.0, for protease treatment (33).

Treatment of PS I with Proteases and NaI

To study the accessibility of PS I subunits to proteases, purified wild type and mutant PS I complexes, wild type thylakoid membranes, and osmotically shocked cells were incubated with protease at a final chlorophyll concentration of 200 µg/ml. The protease reaction conditions are listed in Table II. To remove peripheral subunits from the PS I core, purified wild type PS I complex was incubated with 3 M NaI for 30 min on ice (34). The samples were diluted with an excess amount of 10 mM MOPS-HCl, pH 7.0, 0.05% Triton X-100, and desalted by ultrafiltration through a Centricon-100 (Amicon).

Table II. Reaction conditions of proteases treatment


Proteases Thermolysin (EC 3.4.24.4) Gln-C (EC 3.4.21.19) Chymotrypsin (EC 3.4.21.1) Papain (EC 3.4.22.2) Lys-C (EC 3.4.21.50) Trypsin (EC 3.4.21.4) Clostripain (EC 3.4.22.8) Pepsin (EC 3.4.23.1)

Specificity ^[VILWMF] [E]^ [YFW]^ [RKILG]^ [K]^ [KR]^ [R]^ [FLYWI]^
Source Bacillus thermoproteolyticus (Sigma) Staphylococcus aureus (Boehringer Mannheim) Bovine pancreas (Boehringer Mannheim) Carica papaya (Boehringer Mannheim) Pseudomonas aeruginosa (Promega Biotech) Porcine pancreas (Promega Biotech) Clostridium histolyticum (Promega Biotech) Porcine stomach (Boehringer Mannheim)
Final protease concentration 250 µg/mg  Chlb 250 µg/mg Chl 250 µg/mg Chl 10 µg/mg Chl 250 µg/mg Chl 250 µg/mg Chl 250 µg/mg Chl 250 µg/mg Chl
Proteolysis conditiona 10 mM MOPS (pH 7.0); 5 mM CaCl2 50 mM NH4HCO3 (pH 7.8) 50 mM Tris-HCl (pH 8.0); 10 mM CaCl2 10 mM MOPS (pH 7.0); 0.5 mM EDTA; 1.5 mM CySH 25 mM Tris-HCl (pH 7.5); 1 mM EDTA 50 mM Tris-HCl (pH 8.0); 1 mM CaCl2 20 mM Tris-HCl (pH 7.5); 1 mM CaCl2; 2 mM DTTc 20 mM NaH2PO4 (pH 4.0)
Incubation 37 °C, 30 min 15 °C, 30 min 25 °C, 1 h 25 °C, 1 h 37 °C, 1 h 37 °C, 1 h 37 °C, 1 h 37 °C, 1 h
Termination 20 mM EDTA 20 mM PMSF 20 mM PMSF 20 mM PMSF 20 mM PMSF 20 mM PMSF 20 mM EDTA 20 µM pepstatin A

a 0.05% Triton X-100 was added for purified PS I complexes.
b Chl, chlorophyll.
c DTT, dithiothreitol.

Oxygen Uptake Measurements

Purified PS I complexes that had been treated with proteases were used for oxygen uptake measurements. In a total volume of 1 ml, PS I containing 10 µg of chlorophyll was used for the reaction. PS II inhibitor, electron donors, and electron acceptor were added to a final concentration of 50 µM 3-(3,4-dichlorophenyl)-1,1-dimethyl urea, 1 mM ascorbate, 1 mM 3,6-diaminodurene, and 2 mM methyl viologen. Oxygen uptake was measured on the Oxygen Monitoring System (Hansatech, UK) under the light density of 2430 µmol m-2 s-1.

Preparation of Antibodies

Domain-specific antibodies were generated using overexpressed fusion proteins as antigens. DNA fragments coding the appropriate peptides in PsaA and PsaB of Synechocystis sp. PCC 6803, PsaA2 for residues A2-TISPPEREAKAKVSVDNNPVPTSFEKWGKPGHFDRTL of PsaA, and PsaB450 for residues B450-QILIEPVFAQWIQATSGKALYGFDVLLSNPDSIASTTGAAWLPGWLDAINSGINSLF of PsaB were amplified by polymerase chain reaction and inserted into expression vector pGEX-KG between EcoRI and XhoI sites. The expression of fusion proteins was induced by isopropyl beta -D-thiogalactopyranoside. Cells were harvested by centrifugation and lysed by a probe sonicator. The fusion proteins in inclusion bodies were isolated from membranes by centrifugation through 10% sucrose and applied directly for electrophoresis. The gel was stained by Coomassie Blue. The fusion proteins were excised from the gel and used for raising antibodies at Cocalico Biological. Antibody anti-PsaB718 was raised against the C terminus of PsaB (35). Antisera were evaluated by Western blotting against both thylakoid membranes and purified PS I complex. All three domain-specific antibodies anti-PsaA2, anti-PsaB450, and anti-PsaB718 recognized only the 66-kDa diffuse band corresponded to the comigrating PsaA and PsaB proteins.

Analytical Gel Electrophoresis, Immunodetection, and N-terminal Amino Acid Sequencing

Isolated PS I complexes and photosynthetic membranes were solubilized at 37 °C for 2 h with 1% SDS and 0.1% 2-mercaptoethanol. Proteins were resolved by a modified Tricine/urea SDS-PAGE for better resolution of the PS I subunits (10). After electrophoresis, gels were electrotransferred to Immobilon-P polyvinylidene difluoride membranes (Millipore). Immunodetection was performed using the enhanced chemiluminescence reagents (Amersham Corp.). For sequencing of N termini of proteolytic cleavage fragments, peptides were separated by electrophoresis, transferred to Immobilon-P membranes, stained with Coomassie Blue containing 1% acetic acid for several minutes, destained with 50% methanol, and rinsed with deionized water. The N-terminal sequences were determined on an Applied Biosystems 477A Sequencer.


RESULTS

Activity of the Protease-treated PS I Complexes

In this study, we used limited proteolysis to map surface domains in the PsaA-B core of PS I. To examine activity of the protease-treated complexes, we determined PS I-mediated oxygen consumption rates by Mehler reaction (36, 37). Purified wild type PS I complexes were treated by eight proteases and employed in oxygen uptake measurements (Table III). The PS I activity of untreated sample was 377.5 µmol of O2/mg of chlorophyll/h. The PS I activities in all eight protease treatments ranged from 99 to 133% control activity. An active reaction center and functional electron transfer chain are required for the PS I activity that is measured by the oxygen uptake. Thus the protease treatments did not damage the electron transfer chain within the PS I complex. This may imply that the limited proteolysis could only access extramembrane loops. In most protease-treated samples, the PS I activity was higher than that in the untreated control. Proteases might have degraded the extramembrane loops and small subunits, thereby facilitating access of electron donor or acceptor to the electron transfer centers in the PS I complexes.

Table III. Oxygen measurements of protease-treated PS I complexes


Protease treatment PS I activity (µmol O2/mg chlorophyll · h)

Control 377.5
Chymotrypsin 416.0
Clostripain 371.9
Glu-C 408.8
Lys-C 472.8
Papain 380.9
Pepsin 431.5
Thermolysin 455.9
Trypsin 503.4

Accessibility of PsaA and PsaB to Proteases

Purified PS I complexes from the wild type strain were treated with proteases to study the accessibility of cleavage sites in PsaA and PsaB. The PS I complexes were treated with different concentrations of proteases and the resulting fragments were stained by Coomassie Blue or immunodetected by the three domain-specific antibodies (Fig. 1). The apparent masses of protein fragments were determined from the migration of prestained protein molecular weight standards (Life Technologies, Inc.) upon electrophoresis. The protein fragments that were visible in Coomassie Blue staining were subjected to N-terminal amino acid sequencing. Three criteria, the N-terminal sequences, the apparent mass, and the immunoreactivities of proteolytic fragments, were used to identify the proteolytic fragments (Table IV).


Fig. 1. Accessibility of the wild type PS I complex to proteases. Purified wild type PS I complexes were incubated with different concentrations of proteases for the times indicated in Table II. The concentrations 0-3 were 0, 0.4, 2, and 10 µg of papain/mg of chlorophyll in papain treatment and 0, 10, 50, and 250 µg of protease/mg of chlorophyll in other protease treatments. The samples were resolved by Tricine/urea/SDS-PAGE and transferred to the Immobilon-P polyvinylidene difluoride membranes. The protein fragments were detected by Coomassie Blue (CB) staining (25 µg of chlorophyll used) and Western blotting (5 µg of chlorophyll used) with three domain-specific antibodies. The clostripain and pepsin treatments are not shown here. The molecular masses of protein fragments were determined from migration of the following protein markers: insulin (2.9 kDa), bovine trypsin inhibitor (5.8 kDa), lysozyme (14.7 kDa), beta -lactoglobulin (18.5 kDa), carbonic anhydrase (28.9 kDa), and ovalbumin (44.0 kDa).
[View Larger Version of this Image (67K GIF file)]

Table IV. N-terminal amino acid sequence analysis of the proteolytic fragments in Fig. 1

The position of the first amino acid was identified after comparison with the deduced amino acid sequence of PsaA and PsaB.

Proteolytic fragments N-terminal sequence Position of the first amino acid Predicted fragment Apparent mass Predicted mass

kDa kDa
ThI ATKFPKF PsaB, 2 PsaB, 2-497 45.0 54.7
ThII INSGINS PsaB, 498 PsaB,498-731 23.8 26.4
ThIII WGIGHS PsaB, 295 PsaB, 295-497 16.2 22.1
ThIV ILNAHKG PsaB, 304 PsaB, 304-497 15.2 21.1
GlIII KQILIE PsaB, 449 PsaB, 449-731 27.6 31.7
ChI SQDXA PsaB, 9 PsaB, 9-506 43.2 54.8
PalII QATXGK PsaB, 462 PsaB, 462-731 26.2 30.1
TrI WGXPG PsaA, 28 PsaA, 28-? 53.6 ?

The ThII, GlIII, and PaIII fragments were deduced accurately from their N-terminal sequence and from their immunodetection by anti-PsaB718 showing that they contain the C terminus of PsaB. The ThI, ThIII, ThIV, and ChI fragments were recognized by the anti-PsaB450 antibody indicating that they contain the PsaB450 peptide. The ThI fragment also contained the N terminus of PsaB and showed a similar accumulation pattern as the ThII fragment. The immunodetection pattern and apparent mass imply that these fragments resulted from a single cleavage at Ile-498 of PsaB. The ThIII and ThIV fragments were predicted with the same C terminus of the ThI fragment and matched the immunodetection and apparent mass. They may have resulted from the further cleavage of the ThI fragment as their accumulation followed that of ThI. The N terminus of the ChI fragment resulted from the cleavage at Phe-8 of PsaB protein. The immunodetection and apparent mass of the ChI fragment is similar to the ThI fragment, thus the C terminus of the ChI fragment should result from a cleavage close to Ile-498. The only reasonable site to generate C terminus of the ChI fragment is Phe-506. When the PS I complexes were treated with trypsin, the signals corresponding to the intact PsaA were decreased significantly when detected by anti-PsaA2. Also, a diffused band that migrated slightly faster than the PsaA-B band was visible in Coomassie Blue staining. This can be explained as a cleavage in the N-terminal sequence of PsaA. The N-terminal sequence of the TrI fragment revealed the cleavage site in the N-terminal extramembranal domain of PsaA. Thus these fragments, grouped as type I fragments, could be identified with accuracy. Similar to many membrane proteins, the electrophoretic behavior of the PS I core proteins was anomalous compared with the migration of soluble proteins. The comigrating PsaA and PsaB formed the 66-kDa diffuse band in PAGE, whereas the deduced mass is more than 80 kDa. The predicted mass was higher than the apparent mass. This was also true for the type I fragments and was considered during the prediction of the other fragments.

Table V lists the results of Western blotting, the apparent mass, and the predicted proteolysis regions for the protein fragments that could be immunodetected with domain-specific antibodies. The identity of these fragments could be predicted by several ways. The prediction of type 1 fragments was described in the previous paragraph. Type 2 and type 3 fragments contained epitope for the N terminus of PsaA or epitope at the C terminus of PsaB, as shown by the immunodetection results. Based on their apparent mass, there was only one reasonable cleavage site for the fragments of type 2. For example, the GlV fragment, a 44.5-kDa polypeptide recognized by anti-PsaA2, could result from the proteolysis at Glu-512 in PsaA with a predicted mass of 47.5 kDa. The adjacent Glu-C cleavage sites were Glu-342 or Glu-695 in PsaA which made the predicted mass of 37.9 or 76.9 kDa unreasonable for GlV. In type 3 fragments, there were several possible cleavage sites located within one extramembrane loop or in a region containing two extramembrane loops. For example, the GlII fragment, a 33.7-kDa peptide immunodetected with anti-PsaA2, could result from four reasonable cleavages between Glu-323 and Glu-342 in PsaA with the predicted mass from 35.8 to 37.9 kDa. These four possible cleavage sites were located in the E loop. The LyI fragment is the only type 4 fragment. It accumulated similarly as the TrI fragment, so it was predicted to have the similar cleavage at the N-terminal loop of PsaA. The type 5 fragments contained the peptide PsaB450 but there was not enough data to identify them accurately. Overall, the limited proteolysis of the wild type PS I provided extensive information about the residues that are exposed on the surface of the PS I complex.

Table V. Accessibility of PsaA and PsaB to proteases, the predicted proteolysis sites


Proteolytic fragments Immunodetection Apparent mass Predicted fragment Accessible site locationa Predicted mass Prediction type

kDa kDa
ThI Anti-PsaB450 45.0 PsaB, 2-497 PsaB, H 54.7 1
ThII Anti-PsaB718 23.8 PsaB, 498-731 PsaB, H 26.4 1
ThIII Anti-PsaB450 16.2 PsaB, 295-497 PsaB, E and H 22.1 1
ThIV Anti-PsaB450 15.2 PsaB, 304-497 PsaB, E and H 21.1 1
GlI Anti-PsaB450 and B718 41.2 PsaB, 304-731 PsaB, E 47.5 2
GlII Anti-PsaA2 33.7 PsaA, 1-(323-342) PsaA, E 35.8-37.9 3
GlIII Anti-PsaB450 and B718 27.6 PsaB, 449-731 PsaB, H 31.7 1
GlIV Anti-PsaA2 21.0 PsaA, 1-(241-251) PsaA, D 26.7-27.8 3
GlV Anti-PsaA2 44.5 PsaA, 1-512 PsaA, H 56.7 2
GlVI Anti-PsaA2 29.1 PsaA, 1-(323-342) PsaA, E 35.8-37.9 3
GlVII Anti-PsaA2 12.0 PsaA, 1-101 PsaA, B 11.5 2
GlVIII Anti-PsaB450 and B718 45.9 PsaB, (202-267)-731 PsaB, D 51.7-58.5 3
GlIX Anti-PsaB450 36.9 PsaB, ? PsaB, ? ? 5
GlX Anti-PsaB450 23.4 PsaB, ? PsaB, ? ? 5
ChI Anti-PsaB450 43.2 PsaB, 9-506 PsaB, A and H 54.8 1
ChII Anti-PsaB450 and B718 17.3 PsaB, 445-731 PsaB, H 32.1 4
PaI Anti-PsaA2 40.6 PsaA, 1-(414-433) PsaA, G 45.8-48.1 3
PaII Anti-PsaA2 30.3 PsaA, 1-(280-344) PsaA, D or E 31.1-38.1 3
PaIII Anti-PsaB450 and B718 26.2 PsaB, 462-731 PsaB, H 30.1 1
PaIV Anti-PsaA2 22.7 PsaA, 1-(223-269) PsaA, D 24.7-29.8 3
PaV Anti-PsaA2 13.0 PsaA, 1-(120-151) PsaA, B 13.6-16.7 3
PaVI Anti-PsaB718 20.8 PsaB, (477-549)-731 PsaB, H or I 21.1-28.6 3
PaVII Anti-PsaB718 13.7 PsaB, (595-614)-731 PsaB, J 13.6-15.7 3
PaVIII Anti-PsaB450 42.6 PsaB, ? PsaB, ? ? 5
PaIX Anti-PsaB450 36.4 PsaB, ? PsaB, ? ? 5
LyI None 53.4 PsaA, ? PsaA, A ? 4
TrI None 53.6 PsaA, 28-? PsaA, A ? 1
TrII Anti-PsaB450 39.5 PsaB, ? PsaB, ? ? 5
TrIII Anti-PsaB450 16.7 PsaB, ? PsaB, ? ? 5
PeI Anti-PsaB450 41.4 PsaB, ? PsaB, ? ? 5
PeII Anti-PsaB450 35.9 PsaB, ? PsaB, ? ? 5
PeIII Anti-PsaB450 14.6 PsaB, ? PsaB, ? ? 5
ClI Anti-PsaB450 and B718 43.8 PsaB, 293-731 PsaB, E 48.8 2

a For nomenclature of loops, see Fig. 4.

Treatment of Mutant PS I Complexes with Proteases

As the components of the multiprotein PS I complex, the PsaA and PsaB core proteins interact with the small subunits. To study these interactions, subunit-deficient mutant PS I complexes (Table I) and NaI-treated PS I complexes were used for limited proteolytic treatments. Different PS I complexes were incubated with proteases, and resulting fragments were detected by Western blotting (Fig. 2). When specific small subunits were absent, the proteolytic sites in the core proteins that are shielded by the small subunits were expected to be exposed to proteases. Indeed, additional peptide fragments that reacted with the three domain-specific antibodies were obtained in mutant PS I complexes compared with the protease-treated wild type PS I complexes. The apparent mass and the immunoreactivity were used in prediction of the additional fragments (Table VI).


Fig. 2. Treatment of the subunit-deficient PS I complexes with proteases. The PS I complexes were incubated with different proteases at the final concentration as described in Table II. The samples equivalent to 5 µg of chlorophyll were analyzed by Tricine/urea/SDS-PAGE and Western blotting with three domain-specific antibodies. For treatments: -, control; Ch, chymotrypsin; Cl, clostripain; Gl, Glu-C; Ly, Lys-C; Pa, papain; Pe, pepsin; Th, thermolysin; and Tr, trypsin.
[View Larger Version of this Image (56K GIF file)]

Table VI. Additional proteolytic fragments upon treatment of mutant PS I complexes with proteases


Proteolytic fragments Mutant PS I complexes Immunodetection Apparent mass Predicted fragment Predicted mass Accessible site locationa

kDa kDa
ChA NaI Anti-PsaA2 15.1 PsaA, 1-(144-190) 15.9 -21.2 PsaA, B, C
ChB NaI, ADC4 Anti-PsaB718 15.9 PsaB (551-571)-731 18.8 -20.8 PsaB, I
ChC AEK2 Anti-PsaA2 30.4 PsaA, 1-(277-341) 30.8 -37.7 PsaA, D, E
ChD AEK2 Anti-PsaA2 19.8 PsaA, 1-(189-289) 21.1 -32.0 PsaA, C, D
ChE AEK2 Anti-PsaA2 17.6 PsaA, 1-(189-289) 21.1 -32.0 PsaA, C, D
ChF AEK2 Anti-PsaA2 11.4 PsaA, 1-(100-156) 11.4 -17.3 PsaA, B
ClA NaI, AEK2 Anti-PsaA2 49.1 PsaA, 1-(462-571) 51.5 -63.1 PsaA, H, I
ClB NaI Anti-PsaB718 15.9 PsaB, (540-562)-731 19.7 -22.1 PsaB, I
ClC AEK2 Anti-PsaA2 24.0 PsaA, 1-312 34.6 PsaA, E
LyA NaI, ADC4, AFK6, AIC9 Anti-PsaB718 15.5 PsaB (543-549)-731 21.1 -21.8 PsaB, I
LyB NaI, AEK2, AFK6, AIC9 Anti-PsaB718 16.8 PsaB, 534-731 22.7 PsaB, I
LyC NaI, ADC4 Anti-PsaB718 28.2 PsaB, (403-450)-731 31.0 -36.8 PsaB, G, H
ThA NaI, ADC4, AEK2 Anti-PsaB718 15.5 PsaB (532-570)-731 19.0 -22.9 PsaB, I
ThB AEK2 Anti-PsaB718 26.0 PsaB, (440-498)-731 26.4 -32.6 PsaB, H
ThC AEK2 Anti-PsaA2 37.4 PsaA, 1-(380-429) 42.0 -47.5 PsaA, F, G
ThD AEK2 Anti-PsaA2 29.0 PsaA, 1-(314-343) 34.8 -38.0 PsaA, E
ThE AEK2 Anti-PsaA2 22.8 PsaA, 1-(222-289) 24.6 -32.0 PsaA, D
ThF AEK2 Anti-PsaA2 14.3 PsaA, 1-(129-192) 14.4 -21.5 PsaA, B, C
TrA AFK6 Anti-PsaA2 40.0 PsaA, 1-(462-519) 51.5 -57.4 PsaA, H
TrB AFK6 Anti-PsaB718 22.7 PsaB, (450-468)-731 29.5 -31.6 PsaB, H
LF NaI, ADC4 Anti-PsaB718 40.0-45.0 PsaB, (158-327)-731 45.0 -63.4 PsaB, C, D, E

a For nomenclature of loops, see Fig. 4.

In general the ADC4, AEK2, and NaI-treated PS I complexes yielded more additional proteolytic fragments than the AFK6 and AIC9 complexes, indicating that the peripheral PS I subunits shield more extramembrane proteolytic sites in the core proteins than the integral membrane proteins. When the ADC4 and NaI-treated PS I complexes were incubated with proteases, PsaA and PsaB were digested much more rapidly than the core proteins in the wild type PS I complexes. The AEK2, AFK6, and AIC9 complexes were more resistant to proteolysis than ADC4 and NaI-treated PS I complexes. The untreated ADC4 and NaI-treated PS I complexes contained 42-kDa fragments detected by anti-PsaA2 and anti-PsaB450. The natural degradation of PsaA is predicted in the H loop. The degradation fragment of PsaB was similar to the ThI fragment that resulted from the cleavage at Ile-498 in the H loop. Therefore, these results suggest that the natural degradation may occur in the H loops of both core proteins.

Information about the protection of PsaA by small subunits can be obtained from the immunodetection data with the anti-PsaA2 antibody. Additional fragments were not observed in the protease treatments of the AIC9 complexes. Therefore, PsaL and PsaI may not shield protease-recognition sites in PsaA from proteolysis. When the PS I complexes from the AFK6 strain were treated with trypsin, the additional 40-kDa TrA fragment was obtained. The TrA fragment could result from a cleavage in the H loop of PsaA. When the PS I complexes of the ADC4 strain were treated with proteases, the major fragments detected by anti-PsaA2 were the 42-kDa degradation fragments. However, when the PS I complexes of the AEK2 strain were treated with proteases, small additional proteolytic fragments (ThC-F, ChC-F, and ClC) resulted from the cleavages in the N-terminal domain of PsaA. Also, a 44-kDa fragment (ClA) resulted from accessible sites in the C-terminal domain of PsaA. The cleavages in the N-terminal domain of PsaA could be detected only upon protease treatment of the PsaE-less AEK2 complexes, implying that the N-terminal domain of PsaA may interact with PsaE. The NaI treatment of PS I complexes removed PsaD, PsaE, and PsaC from the core proteins. When the NaI-treated PS I complexes were treated with proteases, the anti-PsaA2 antibody immunoreacted with the 42-kDa degradation product that was similar to the one in the protease-treated ADC4 complex and also with the large proteolytic fragments similar to the ones in the protease-treated AEK2 complex.

When detected with the anti-PsaB450 antibody, the protease-treated PS I complexes of the AEK2, AFK6, and AIC9 strains contained the similar pattern as the protease-treated wild type PS I proteins. For the protease treatments of the ADC4 and NaI-treated PS I complexes, the 28.2-kDa LyC fragment was detected in addition to the 42-kDa degradation fragment. Some diffused fragments between the 42-kDa fragment and the intact PsaA-B protein were also observed, especially in the NaI-treated PS I complexes. When compared with the detection by the anti-PsaB718 antibody, these fragments did not contain the C-terminal epitope. These fragments could result from the cleavages in the I, J, or K loops which are close to the C terminus of PsaB.

Additional fragments were detected by the anti-PsaB718 antibody in all mutant PS I complexes. The 28.2-kDa LyC fragment that was recognized by the anti-PsaB450 antibody was also immunodetected by the anti-PsaB718 antibody when the ADC4 and NaI-treated PS I complexes were treated with the Lys-C protease. From its apparent mass and the presence of the C-terminal epitope, this fragment was predicted to have N terminus from one of five possible cleavage sites in the G and H loops to the C terminus of PsaB. Proteolysis at these sites should result in fragments with a predicted mass of 31.0-36.8 kDa. When the PS I complexes of AFK6 were treated with trypsin, the 22.7-kDa TrB fragment was detected by the anti-PsaB718 antibody. This fragment could have resulted from a cleavage at Lys-449 or Lys-467 in the H loop of PsaB. In the ADC4 and NaI-treated PS I complexes, an additional 40.0-45.0-kDa fragment shown as LF in Fig. 2 was detected in most protease treatments. This fragment was absent in the untreated PS I complex. The possible cleavage sites may be located in the C, D, and E loops of PsaB with a predicted mass of 45.0-63.4 kDa. However, no such fragment was observed in the AEK2, AFK6, and AIC9 PS I complexes. Therefore, the N-terminal domain of PsaB is protected by PsaD but may not interact with the other subunits.

Previous work has indicated that a 16-kDa proteolytic fragment detected by anti-PsaB718 in thermolysin-treated ADC4 PS I complex resulted from a cleavage at Leu-531 in the I loop of PsaB (28). Similar proteolytic fragments, such as ChB, ClB, LyA, LyB, ThA in different mutant PS I complexes, were detected. These proteolytic fragments could result from cleavages in the I loop of PsaB indicating that the I loop in the C-terminal domain of PsaB may interact with several subunits. In the Lys-C treatments, two close fragments from the cleavages in the I loop of PsaB were obtained in the AFK6, AIC9, and NaI-treated PS I complexes with apparent mass about 15.5 and 16.8 kDa. Only one such fragment was detected in ADC4 and AEK2 each, with a slight difference in their apparent mass. One of the four lysyl residues in the I loop may be involved in the cleavage by the Lys-C endoprotease. The cleavage at Lys-533 may yield a C-terminal fragment with a predicted mass of 22.7 kDa, and the cleavage at Lys-542, Lys-547, or Lys-548 would result in the fragment containing C-terminal epitope with a predicted mass of 21.1-21.8 kDa. According to these results, LyB was predicted as the cleavage at Lys-533 in the AEK2, AFK6, AIC9, and NaI-treated PS I complexes, and LyA might have resulted from the cleavage at one of the other three lysyl residues in the ADC4, AFK6, AIC9, and NaI-treated PS I complexes.

Apparently, numerous proteolytic fragments resulted from the cleavages in the C-terminal domain of PsaB in the mutant PS I complexes indicating the shielding and protection of this domain by the missing small subunits. These results imply that the C-terminal domain of PsaB may play an important role in the assembly of the PS I complex.

Orientation of the N Terminus of the PsaA Protein

The osmotically shocked Synechocystis sp. PCC 6803 cells were treated with trypsin and Lys-C and examined by Western blotting. The thylakoid membranes that had been isolated by usual procedure (38) were used as a control. Two antibodies, anti-PsaD and anti-PsbO, were used to test the intactness of thylakoid membranes after osmotic treatment and during protease digestions. The domain-specific antibody anti-PsaA2 was used to determine the orientation of PsaA (Fig. 3). PsaD, which is located on the n side of photosynthetic membrane, was expected to be exposed to proteases during the treatment. Small fragments in Lys-C and trypsin treatments were recognized by anti-PsaD indicating the digestion of PsaD in membranes from both control and osmotically shocked cells. Digestion of PsaD in the osmotically shocked cells was not as extensive as in isolated membranes. Due to a large amount of cytoplasmic proteins, protease to protein ratio in the cell treatments was expected to be lower than in the thylakoid treatments. If the thylakoid membranes were intact during the protease treatments, PsbO which is located on the p side of photosynthetic membrane was expected to remain intact. In membranes, PsbO was not detected after protease treatment. In contrast, most PsbO remained intact in the osmotically shocked cells. These results showed that the osmotically shocked thylakoid membranes remain largely intact during the protease treatments. In Lys-C and trypsin treatments, significant degradation of PsaA was observed when anti-PsaA2 was used for detection. As described previously, the degradation of PsaA in Lys-C and trypsin treatments resulted from the cleavage in the N-terminal loop of PsaA. Therefore, the N terminus of PsaA was exposed to proteases in the osmotically shocked cells showing that it is on the n side of photosynthetic membranes.


Fig. 3. Transmembrane orientation of the N terminus of the PsaA protein. Thylakoid membranes were isolated from osmotically shocked cells treated by Lys-C and trypsin, and isolated thylakoid membranes were treated by proteases as control. Samples equivalent to 5 µg of chlorophyll were analyzed by Tricine/urea/SDS-PAGE and Western blotting with three antibodies. O.S., osmotically shocked; Ly, Lys-C; Tr, trypsin.
[View Larger Version of this Image (36K GIF file)]


DISCUSSION

PS I is a multisubunit protein complex that contains at least 11 polypeptides in cyanobacteria (1). In this study, we used domain-specific antibodies, limited proteolysis, and subunit-deficient PS I complexes to understand the topography of the PsaA and PsaB proteins that form the catalytic hydrophobic core of PS I. Domain-specific antibodies were generated against specific peptides in PsaA and PsaB. Western blotting with thylakoid membranes and purified PS I complexes showed that the antibodies are specific to PsaA or PsaB. N-terminal amino acid sequences of the fragments recognized by antibodies (Table IV) demonstrated the domain specificity of the antibodies to PsaA and PsaB proteins. The GlIII fragment with the N terminus at Lys-449 of PsaB was recognized by the anti-PsaB450 antibodies, whereas the ThII fragment with the N terminus at Ile-498 of PsaB was not recognized by anti-PsaB450. These results indicated that the specific binding domain of anti-PsaB450 should be located between Lys-449 and Ile-498 of PsaB protein, the corresponding peptide of anti-PsaB450. N terminus of the TrI fragment which was not recognized by anti-PsaA2 started at Trp-28 of PsaA. Therefore anti-PsaA2 specifically recognizes the N terminus of PsaA. Limited proteolysis has been successfully used to probe transmembrane topology of membrane proteins. In these analyses, it is necessary to establish conditions that allow cleavage of the extramembrane loops but not of the transmembrane regions. We ensured integrity of the hydrophobic core of PS I after proteolysis from measuring PS I activity using artificial electron donor and acceptor (Table III).

The structure of cyanobacterial PS I complex at 4-Å resolution has indicated that PsaA and PsaB have 11 transmembrane helices each. These helices span the lipid bilayer completely (26). Based on the available information and the results in this paper, we proposed a model for transmembrane folding of the PsaA and PsaB core proteins (Fig. 4). The homology between PsaA and PsaB proteins implied that they would fold similarly. Therefore, the model in Fig. 4 should be applicable to both PsaA and PsaB proteins. In this model, 11 transmembrane helices span the thylakoid membrane completely with the N termini on the n side of thylakoid membrane. Consequently, the C termini are on the p side of thylakoid membrane (Fig. 4). Such orientation is supported by the following observations. The 4-Å crystal structure indicated clearly the complete spanning of the 11 transmembrane helices (26). The Lys-C and trypsin treatments of the osmotically shocked cells in this paper suggested that the N terminus of PsaA is located on the n side of the thylakoid membrane. Xu and Chitnis (28) showed that the K loop interacts with PsaD which is located on the n side of the thylakoid membrane. Vallon and Bogorad (29) located the G loop on the n side and the F and H loops on the p side by using immunogold labeling. The I loop with the FX binding domain should be located on the n side of the thylakoid membrane. Also, the six n side extramembrane loops contain the majority of the positive residues, which agrees with the "positive inside" rule (39, 40). Therefore, now there is sufficient evidence from different sources that collectively demonstrate the transmembrane orientation of the PsaA and PsaB proteins (Fig. 4).


Fig. 4. A folding model for PS I core proteins PsaA and PsaB. The putative transmembrane helices are based on the hydropathy analyses of PsaA and PsaB from Synechocystis sp. PCC 6803 (30). The 11 transmembrane helices are shown as dark boxes for the N-terminal helices and light boxes for the C-terminal helices and are numbered as I-XI followed by italic letters a-o corresponding to the helices in the 4-Å crystal structure (26) with the starting and ending sites. Extramembrane loops are shown as italic capital letters A-L and as light thin lines. Two alpha -helices that are parallel to the membrane plane (26) are shown as boxes in the J and K loops. The peptides for raising domain-specific antibodies are indicated as dark bold lines with starting and ending sites. In the model, the Right-arrow  and right-arrow  with amino acid residues indicate the identified cleavage site on PsaA and PsaB, respectively. A pair of succ  or right-arrow  coupled with numbers indicate the possible region of cleavage on PsaA and PsaB, respectively. Information from immunogold labeling which showed orientation of some extramembrane loops of PsaA (29) are marked as small boxes in the F, G, and H loops. The large Right-arrow  and right-arrow  with the descriptions indicate the interaction among the small subunits and PsaA and PsaB, respectively. * indicates the information from Ref. 28.
[View Larger Version of this Image (59K GIF file)]

Because of the folded structure of the substrate proteins, proteases cannot cleave at every recognition site in the primary sequence. The accessibility of extramembrane loops in PsaA and PsaB to proteases is determined by folding of the loops. Some loops may form loose conformation that will be exposed readily to proteases. In contrast, some loops may have compact conformation, like the helices that are parallel to the membrane plane. Many protease recognition sites in the compact loops may not be accessible to proteases. Also, the protection from other proteins will reduce the surface exposure of the loops. For these reasons, the accessibility of extramembrane loops in PsaA and PsaB differed for each loop (Fig. 4). The protease recognition sites in the C, F, and K loops of PsaA and PsaB could not be cleaved, whereas the H and E loops of PsaB were readily accessible to proteases. The H loop is on the p side of the thylakoid membrane in the model. It is only one transmembrane helix from the I loop which contains the FX-binding motif and interacts with PsaC on the n side (41, 42). From the arrangement of helices in the 4-Å model of PS I, both I and H loops should be located in the center of the PS I core. The extensive accessibility of the H loop to proteases and its p side location imply that the H loop of PsaB could be accessible to interaction with plastocyanin or cytochrome c6, the electron carriers that transfer electrons from cytochrome b6f complex to the P700 reaction center of PS I complex in the p side of the thylakoid membrane. PsaF is involved in docking of plastocyanin in the plant PS I (7, 19, 20) but not in the cyanobacterial PS I (6, 21). This difference is ascribed to a lysine-rich sequence that is present in the N-terminal region of the plant PsaF but not in the cyanobacterial PsaF (43). Besides PsaF, the H and J loops are the only two domains exposed to p side and located in the center the PS I complex. When the H and J loop sequences of PsaA and PsaB from high plants and cyanobacteria are aligned, there is a major difference in a 12-residue sequence in the H loop of PsaB but not in others (4). This information suggests that the H loop of PsaB in cyanobacterial PS I complex may help the docking of plastocyanin or cytochrome c6 from the p side of the thylakoid membrane and even contribute to the electron transfer from these two electron donors to the P700 reaction center.

In the 4-Å crystal structure of PS I, the C-terminal domains from both PsaA and PsaB core proteins form a cage where the electron transfer chain is located. This important cage is the catalytic center of the PS I complex and is protected by PsaD, PsaC, and PsaE subunits from the n side and by the surface helices l and l' in the J loop of PsaA and PsaB from the p side of the thylakoid membrane (26). The protection of the C-terminal domains in PsaA and PsaB is also observed in the protease treatments of the wild type PS I complex. The only cleavages that may occur in the I, J, K, and L loops were the PaVI and PaVII fragments from the papain treatment accompanying the complete degradation of the small subunits PsaD and PsaF. With intact small subunits, the C-terminal loops I, J, K, and L are well protected from the limited proteolysis. Protection by the small subunits is also shown by the numerous proteolytic fragments from the cleavages in the I loop of PsaB in the mutant PS I complexes (Table VI).

The additional fragments in protease treatments of the subunit-deficient PS I complexes provide information about the interactions between the small subunits and the loops of PsaA and PsaB. PsaE is the only missing subunit in the PS I complex from the AEK2 strain. The additional fragments from the protease treatments of AEK2 complexes indicated that the absence of PsaE resulted in possible cleavages in the B-I loops of PsaA and the I loop of PsaB (Table VI). As an n side subunit, PsaE may interact with the C, E, F, and I loops in the n side of the thylakoid membrane. The cleavages in the p side loops may result from further digestion of the degradation products. Therefore, PsaE may interact with the n side loops in the N-terminal domain of PsaA and the I loops of both PsaA and PsaB (Fig. 4). In the protease treatments of the ADC4 PS I complexes, additional cleavages were located in the C-E and G-I loops of PsaB (Table VI). Thus, PsaD may interact with the n side loops in the N-terminal domain of PsaB and the I loop of PsaB (Fig. 4). Additionally, Xu and Chitnis (28) identified that PsaD may shield the I and K loops of PsaB. When the PS I complexes from the AFK6 and AIC9 strains were treated by proteases, no additional fragments from the N-terminal domains of PsaA and PsaB were observed. The AFK6 and AIC9 mutant PS I complexes do not contain PsaF-PsaJ and PsaI-PsaL, respectively. Therefore, the extramembrane loops in the N-terminal domains of PsaA and PsaB may not interact with these subunits. The trypsin treatment of the AFK6 PS I complex yielded the TrA and TrB fragments. These two fragments resulted from the cleavages in the H loops of PsaA and PsaB (Table VI). Between the two subunits absent in the AFK6 complex, PsaJ is mainly a transmembrane helix, whereas PsaF has been proposed to contain a peripheral domain on the p side of membrane (44). Therefore, the p side domain of PsaF may interact with the H loops of PsaA and PsaB on the p side of the thylakoid membrane (Fig. 4). In the Lys-C treatments of the AFK6 and AIC9 PS I complexes, additional cleavages were observed in the I loop of PsaB. The missing subunits in these mutant PS I complexes may not directly interact with the I loop of PsaB because the predicted positions of these subunits in the 4-Å crystal structure were not close enough to the I loop of PsaB (26). However, chemical cross-linking studies have yielded the following cross-linked products: PsaC-PsaD, PsaC-PsaE, PsaD-PsaL, and PsaE-PsaF (44, 45). The interactions between the cross-linked subunits may cause some conformational changes of PsaD, PsaE, or even PsaC in the mutant PS I complexes. Therefore, the I loop of PsaB that was protected by PsaD and PsaE subunits could be exposed to protease in the AFK6 and AIC9 PS I complexes. Correspondingly, the absence of PsaE may cause the conformational change in PsaF and result in the exposure of the H loops of PsaA and PsaB that are shielded by PsaF. In the thermolysin treatment of the AEK2 PS I complex, the ThB fragment resulted from the cleavage in the H loop of PsaB (Table VI). As described above, PsaF may interact with the H loops of PsaA and PsaB, whereas PsaI, PsaL, and PsaJ may not shield the extramembrane loops of the core proteins (Fig. 4).

In the 4-Å crystal structure of PS I, core proteins PsaA and PsaB contribute their C-terminal domain to form the central cage of PS I core, and the N-terminal domain of PsaA and PsaB may form the peripheral helices. PsaA and PsaB may crossover in the central cage so both the C-terminal domains of PsaA and PsaB may be protected by a single subunit. For this reason, PsaF can interact with both H loops of the core proteins, and PsaE can shield both I loops of PsaA and PsaB (Fig. 4). However, the peripheral helices in one of the two symmetry regions should be donated from one of the core proteins. The absence of PsaE results in further cleavages in the N-terminal domain of PsaA, and the absence of PsaD results in further cleavages in the N-terminal domain of PsaB in the protease treatments of the mutant PS I complexes (Fig. 4). This asymmetrical interaction indicated the arrangement of the N termini of the PsaA and PsaB core proteins related to the PsaD and PsaE subunits. However, the electron microscopy study has revealed that PsaD and PsaE are located in different sides of the central axis, and they do shield different parts of the core proteins (46). Combining this information, we propose a model to distinguish PsaA and PsaB in the 4-Å crystal structure of PS I (Fig. 5). In this model, the region partly covered by PsaD and not by PsaE belongs to PsaB, and the region only covered by PsaE belongs to PsaA. Therefore, our data indicate that the primed helices in the 4-Å map belong to PsaA, and the unprimed helices are assigned to PsaB if the primed and unprimed helices are contributed from each of the core proteins (Fig. 5).


Fig. 5. A topological model for PS I complex. The model is modified from the 4-Å crystal structure (26). The organization of PS I complex is viewed from the top. The PS I subunits are indicated as the regions distinguished by dotted lines with the transmembrane helices (26).
[View Larger Version of this Image (99K GIF file)]

To conclude, the topographical analyses of the PsaA and PsaB proteins have allowed us to examine the accessibility of their extramembrane loops to proteases, the shielding and protection of these loops by small subunits, the location of the N terminus of PsaA, and the assignment of the two core proteins relative to small subunits in the 4-Å map. The biochemical techniques are indeed valuable for deciphering the structure of membrane proteins and to complement the biophysical techniques that cannot be applied readily to the structural analysis of membrane proteins.


FOOTNOTES

*   This work was supported in part by National Science Foundation Grant MCB9696170 and the National Institutes of Health Grant GM53104. This is Journal Paper No. J-17435 of the Iowa Agriculture and Home Economics Experiment Station, Ames, IA, Project No. 3416, and supported by Hatch Act and State of Iowa funds.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    Present address: Dept. of Molecular Plant Biology, University of California, Berkeley, CA 94720.
§   Present address: Dept. of Agronomy, Iowa State University, Ames, IA 50011.
   To whom correspondence should be addressed. Tel.: 515-294-1657; Fax: 515-294-0453; E-mail: chitnis{at}iastate.edu.
1   The abbreviations used are: PS, photosystem; PMSF, phenylmethanesulfonyl fluoride; MOPS, 3-(N-morpholino)propanesulfonic acid; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; PAGE, polyacrylamide gel electrophoresis.
2   D. A. Bryant, personal communication.
3   P. Manna and P. R. Chitnis, unpublished results.

ACKNOWLEDGEMENTS

We thank Dr. James A. Guikema for the anti-PsaB718 antibody. We thank Drs. Petra Fromme, Wolf-Dieter Schubert, Norbert Krauß, and Prof. Wolfram Saenger for insightful discussions.


REFERENCES

  1. Chitnis, P. R., Xu, Q., Chitnis, V. P., and Nechushtai, R. (1995) Photosynth. Res. 44, 23-40
  2. Fromme, P. (1996) Curr. Opin. Struct. Biol. 6, 473-484 [CrossRef][Medline] [Order article via Infotrieve]
  3. Chitnis, P. R. (1996) Plant Physiol. (Bethesda) 111, 661-669 [Free Full Text]
  4. Golbeck, J. H. (1994) in The Molecular Biology of Cyanobacteria (Bryant, D. A., ed), pp. 179-220, Kluwer Academic Publishers Group, Dordrecht, The Netherlands
  5. Kuhn, M., Fromme, P., and Krabben, L. (1994) Trends Biochem. Sci. 19, 401-402 [Medline] [Order article via Infotrieve]
  6. Xu, Q., Yu, L., Chitnis, V. P., and Chitnis, P. R. (1994) J. Biol. Chem. 269, 3205-3211 [Abstract/Free Full Text]
  7. Haehnel, W., Jansen, T., Gause, K., Klosgen, R. B., Stahl, B., Michl, D., Huvermann, B., Karas, M., and Herrmann, R. G. (1994) EMBO J. 13, 1028-1038 [Abstract]
  8. Oh-oka, H., Takahashi, Y., Kuriyama, K., Saeki, K., and Matsubara, H. (1988) J. Biochem. (Tokyo) 103, 962-968 [Abstract]
  9. Zilber, A., and Malkin, R. (1988) Plant Physiol. (Bethesda) 88, 810-814
  10. Xu, Q., Jung, Y.-S., Chitnis, V. P., Guikema, J. A., Golbeck, J. H., and Chitnis, P. R. (1994) J. Biol. Chem. 269, 21512-21518 [Abstract/Free Full Text]
  11. Lelong, C., Setif, P., Lagoutte, B., and Bottin, H. (1994) J. Biol. Chem. 269, 10034-10039 [Abstract/Free Full Text]
  12. Li, N., Zhao, J. D., Warren, P. V., Warden, J. T., Bryant, D. A., and Golbeck, J. H. (1991) Biochemistry 30, 7863-7872 [Medline] [Order article via Infotrieve]
  13. Chitnis, P. R., and Nelson, N. (1992) Plant Physiol. (Bethesda) 99, 239-246
  14. Sonoike, K., Hatanaka, H., and Katoh, S. (1993) Biochim. Biophys. Acta 1141, 52-57 [Medline] [Order article via Infotrieve]
  15. Strotmann, H., and Weber, N. (1993) Biochim. Biophys. Acta 1143, 204-210 [Medline] [Order article via Infotrieve]
  16. Rousseau, F., Setif, P., and Lagoutte, B. (1993) EMBO J. 12, 1755-1765 [Abstract]
  17. Yu, L., Zhao, J., Mühlenhoff, U., Bryant, D. A., and Golbeck, J. H. (1993) Plant Physiol. (Bethesda) 103, 171-180 [Abstract/Free Full Text]
  18. Chitnis, P. R., Chitnis, V. P., Xu, Q., Jung, Y.-S., Yu, L., and Golbeck, J. H. (1995) in Photosynthesis: From Light to Biosphere (Mathis, P., ed), Vol. 2, pp. 17-22, Kluwer Academic Publishers Group, Dordrecht, Netherlands
  19. Wynn, R. M., Luong, C., and Malkin, R. (1989) Plant Physiol. (Bethesda) 91, 445-449
  20. Hippler, M., Ratajczak, R., and Haehnel, W. (1989) FEBS Lett. 250, 280-284 [CrossRef]
  21. Chitnis, P. R., Purvis, D., and Nelson, N. (1991) J. Biol. Chem. 266, 20146-20151 [Abstract/Free Full Text]
  22. Chitnis, V. P., and Chitnis, P. R. (1993) FEBS Lett. 336, 330-334 [CrossRef][Medline] [Order article via Infotrieve]
  23. Xu, Q., Hoppe, D., Chitnis, V. P., Odom, W. R., Guikema, J. A., and Chitnis, P. R. (1995) J. Biol. Chem. 270, 16243-16250 [Abstract/Free Full Text]
  24. Xu, Q., Odom, W. R., Guikema, J. A., Chitnis, V. P., and Chitnis, P. R. (1994) Plant Mol. Biol. 26, 291-302 [Medline] [Order article via Infotrieve]
  25. Krauß, N., Hinrichs, W., Witt, I., Fromme, P., Pritzkow, W., Dauter, Z., Betzel, C., Wilson, K. S., Witt, H. T., and Saenger, W. (1993) Nature 361, 326-331 [CrossRef]
  26. Krauß, N., Schubert, W.-D., Klukas, O., Fromme, P., Witt, H. T., and Saenger, W. (1996) Nat. Struct. Biol. 3, 965-973 [Medline] [Order article via Infotrieve]
  27. Boekema, E. J., Boonstra, A. F., Dekker, J. P., and Rögner, M. (1994) J. Bioenerg. Biomemb. 26, 17-29 [Medline] [Order article via Infotrieve]
  28. Xu, Q., and Chitnis, P. R. (1995) Plant Physiol. (Bethesda) 108, 1067-1075 [Abstract/Free Full Text]
  29. Vallon, O., and Bogorad, L. (1993) Eur. J. Biochem. 214, 907-915 [Abstract]
  30. Fish, L. E., Kuck, U., and Bogorad, L. (1985) J. Biol. Chem. 260, 1413-1421 [Abstract]
  31. Reilly, P., Hulmes, J. D., Pan, Y.-C. E., and Nelson, N. (1988) J. Biol. Chem. 263, 17658-17662 [Abstract/Free Full Text]
  32. Arnon, D. (1949) Plant Physiol. (Bethesda) 24, 1-14
  33. Tae, G. S., and Cramer, W. A. (1994) Biochemistry 33, 10060-10068 [Medline] [Order article via Infotrieve]
  34. Xu, Q., Armbrust, T. S., Guikema, J. A., and Chitnis, P. R. (1994) Plant Physiol. (Bethesda) 106, 1057-1063 [Abstract/Free Full Text]
  35. Henry, R. L., Takemoto, L. J., Murphy, J., Gallegos, G. L., and Guikema, J. A. (1992) Plant Physiol. Biochem. 30, 357-364 [Medline] [Order article via Infotrieve]
  36. Mehler, A. H. (1951) Arch. Biochem. Biophys. 33, 65-77
  37. Mehler, A. H. (1951) Arch. Biochem. Biophys. 34, 339-351
  38. Chitnis, V. P., Xu, Q., Yu, L., Golbeck, J. H., Nakamoto, H., Xie, D.-L., and Chitnis, P. R. (1993) J. Biol. Chem. 268, 11678-11684 [Abstract/Free Full Text]
  39. von Heijne, G., and Gavel, Y. (1988) Eur. J. Biochem. 174, 671-674 [Abstract]
  40. von Heijne, G. (1988) Biochim. Biophys. Acta 947, 307-333 [Medline] [Order article via Infotrieve]
  41. Smart, L. B., Warren, P. V., Golbeck, J. H., and McIntosh, L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1132-1136 [Abstract]
  42. Warren, P. V., Smart, L. B., McIntosh, L., and Golbeck, J. H. (1993) Biochemistry 32, 4411-4419 [Medline] [Order article via Infotrieve]
  43. Hippler, M., Reichert, J., Sutter, M., Zak, E., Altschmied, L., Schröer, U., Herrmann, R. G., and Haehnel, W. (1996) EMBO J. 15, 6374-6384 [Abstract]
  44. Armbrust, T. S., Chitnis, P. R., and Guikema, J. A. (1996) Plant Physiol. (Bethesda) 111, 1307-1312 [Abstract/Free Full Text]
  45. Xu, Q., Chitnis, V. P., Ke, A., and Chitnis, P. R. (1995) in Photosynthesis: From Light to Biosphere (Mathis, P., ed), Vol. 2, pp. 87-90, Kluwer Academic Publishers Group, Dordrecht, Netherlands
  46. Kruip, J., Chitnis, P. R., Lagoutte, B., Rogner, M., and Boekema, E. J. (1997) J. Biol. Chem. 271, 17061-17069 [CrossRef]
  47. Cohen, Y., Chitnis, V. P., Nechushtai, R., and Chitnis, P. R. (1993) Plant Mol. Biol. 23, 895-900 [Medline] [Order article via Infotrieve]
  48. Chitnis, P. R., Reilly, P. A., and Nelson, N. (1989) J. Biol. Chem. 264, 18381-18385 [Abstract/Free Full Text]
  49. Chitnis, P. R., Reilly, P. A., Miedel, M. C., and Nelson, N. (1989) J. Biol. Chem. 264, 18374-18380 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.